Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,147

Employees1,147

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,147

Employees1,147

EXEL Key Statistics

Market cap

11.39B

Market cap11.39B

Price-Earnings ratio

17.41

Price-Earnings ratio17.41

Dividend yield

—

Dividend yield—

Average volume

2.40M

Average volume2.40M

High today

$42.55

High today$42.55

Low today

$40.54

Low today$40.54

Open price

$41.96

Open price$41.96

Volume

1.67M

Volume1.67M

52 Week high

$49.62

52 Week high$49.62

52 Week low

$32.38

52 Week low$32.38

Stock Snapshot

The current Exelixis(EXEL) stock price is $42.48, with a market capitalization of 11.39B. The stock trades at a price-to-earnings (P/E) ratio of 17.41.

On 2026-02-02, Exelixis(EXEL) stock moved within a range of $40.54 to $42.55. With shares now at $42.48, the stock is trading +4.8% above its intraday low and -0.2% below the session's peak.

Trading activity shows a volume of 1.67M, compared to an average daily volume of 2.4M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $32.38.

EXEL News

TipRanks 4h

Exelixis reports zanzalintinib new drug application accepted for review by FDA

Exelixis (EXEL) announced that its new drug application for zanzalintinib, in combination with atezolizumab, has been accepted for review in the U.S. for the tr...

TipRanks 4h

Exelixis price target raised to $49 from $48 at Morgan Stanley

Morgan Stanley analyst Sean Laaman raised the firm’s price target on Exelixis (EXEL) to $49 from $48 and keeps an Equal Weight rating on the shares. Published...

Simply Wall St 1d

Is Exelixis Using Zanzalintinib To Quietly Redefine Its Post-Cabometyx Strategy?

Exelixis recently submitted a US FDA application for its next-generation cancer drug zanzalintinib, seeking approval in combination with Roche’s Tecentriq for p...

Analyst ratings

50%

of 22 ratings

Buy

45.5%

Hold

50%

Sell

4.5%

More EXEL News

Nasdaq 3d

EXEL Makes Notable Cross Below Critical Moving Average

In trading on Thursday, shares of Exelixis Inc (Symbol: EXEL) crossed below their 200 day moving average of $38.49, changing hands as low as $38.27 per share. E...

TipRanks 6d

Exelixis price target raised to $52 from $49 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Exelixis (EXEL) to $52 from $49 and keeps a Buy rating on the shares. The company issued “encouraging” 2026 fi...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.